BLASUBCUTANEOUSINJECTABLE
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROLVEDON (eflapegrastim-xnst) is a long-acting granulocyte colony-stimulating factor (G-CSF) analog approved as a leukocyte growth factor for subcutaneous injection. It is designed to reduce the incidence of chemotherapy-induced neutropenia (febrile neutropenia) in cancer patients receiving myelosuppressive chemotherapy. The drug mechanism leverages sustained G-CSF signaling to promote neutrophil production and mobilization.
$0.662MPart D
PeakEarly-stage peak adoption with modest Medicare utilization suggests moderate team size and growth-phase commercial operations.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ROLVEDON is a recently approved specialty oncology biologic in peak commercial phase with modest current market penetration (125 Part D claims in 2023). Joining this team offers opportunity to drive market share growth against established competitors in a stable, high-value indication with strong clinical rationale.
Brand ManagerRegional/Territory Sales Manager
Worked on ROLVEDON at Spectrum Dynamics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.